Diet pills will be extinguished?
Yuan Jiandong, chairman of Borui Pharmaceutical, claimed at an exchange meeting that he had reduced his weight from 91 kilograms to 76 kilograms with the weight loss drugs developed by the company. Although phase II clinical trials of GLP-1 drug BGM0504 injections have begun, the company is still anxious to let people know. In December last year, when the product was approved for clinical use, the company also advertised it. However, after entering mid-September, Borui's stock price has not moved, and the company disclosed on September 22 to remind everyone. GLP-1 does not do weight loss indications, in fact, it is useless. At present, the innovative GLP-1 companies that are clearly developing indications for weight loss include Borui, Gan & Lee, Zhongsheng, Lepu, etc., with varying progress, and it will take one or two years to go on the market at the earliest. Some institutions said to add injection pen manufacturers, but the market did not buy it for the time being. At present, many companies are crowding out of the single wooden bridge, just to quickly come up with products that can be realized, and a little slower will become a red ocean. Pharmaceutical innovation is not to engage in new energy vehicles, and one can be far ahead in three or two years. Without more than ten years of continuous solid research and development, it is difficult for the pharmaceutical industry to have technology accumulation and achievement transformation. In the past, the environment allowed biotechs to grow slowly, but companies had to pursue quick profits.
